OBIZUR 500U 500U/ml powder and solvent for solution for injection BAXALTA ORIGINAL MEDICINE
Chemical substance: susoctocog alfa
Active substance
Results for the substance susoctocog alfa
1 result
About this active substance
Susoctocog alfa is a recombinant factor VIII used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It replaces the missing or deficient factor VIII needed for normal blood clotting.
The medication is administered via intravenous injection, as directed by a doctor. The dosage and frequency of administration depend on the severity of the condition and the patient's response to treatment.
Patients should be aware of potential side effects, such as injection site reactions, fever, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, headache, and fever. In rare cases, severe reactions such as the development of factor VIII inhibitors or anaphylactic reactions may occur. Patients should be informed of these risks before starting treatment.
The medication is administered via intravenous injection, as directed by a doctor. The dosage and frequency of administration depend on the severity of the condition and the patient's response to treatment.
Patients should be aware of potential side effects, such as injection site reactions, fever, or allergic reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include injection site reactions, headache, and fever. In rare cases, severe reactions such as the development of factor VIII inhibitors or anaphylactic reactions may occur. Patients should be informed of these risks before starting treatment.